All In Biotech

Drug Trial Radar · NCT07862595

A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)

A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Analgesic Effects and Safety of MK-6916 for Acute Pain Following Bunionectomy

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

380

Planned (sponsor's estimate)

Start

Nov 2, 2026

Primary completion

Jun 10, 2027

Study completion Jun 10, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new treatments for pain. While there are many approved treatments for pain, the treatments do not work well for everyone. People can also become addicted to certain pain medicines. Researchers designed a trial medicine called MK-6916 to treat pain. The goal of the trial is to learn if at least 1 dose of MK-6916 works better than placebo to lessen pain. A placebo looks like the trial medicine but has no trial medicine in it. Using a placebo helps researchers better understand the effects of the trial medicine.

Conditions

  • Pain Management

Interventions

  • MK-6916Drug

    120 mg or 70 mg oral tablet given every 12 hours (q12h) for 48 hours.

  • Hydrocodone/acetaminophen (HB/APAP)Drug

    Hydrocodone 5 mg/acetaminophen 325 mg given as oral capsule every 6 hours (q6h) for 48 hours.

  • MK-6916 PlaceboDrug

    Placebo oral table given every 6 hours (q6h) for 48 hours

  • Rescue MedicationDrug

    Participants requesting rescue medication may receive protocol-specified rescue medication. Rescue treatment consists of open-label oxycodone immediate release (IR) oral tablet 5 mg given every 6 hours (q6h) (given in 5 mg increments for a maximum dose of 10 mg q6h). Participants should be encouraged to wait 1 hour after administration of the first dose of oxycodone 5 mg before administering a second dose. Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sum of the Pain Intensity Difference 0 to 48 Hours (SPID48)Time frame: Up to approximately 48 hours

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Pharmacology of Miami ( Site 0718)

    Miami, Florida · Recruiting

  • ForCare Clinical Research ( Site 0705)

    Tampa, Florida · Recruiting

  • Atlanta Center for Medical Research ( Site 0708)

    Atlanta, Georgia · Recruiting

  • Gateway Clinical Trails, Llc ( Site 0701)

    O'Fallon, Illinois · Recruiting

  • Legent Orthopedic & Spine Hospital ( Site 0711)

    Bellaire, Texas · Recruiting

  • Memorial Hermann Village ( Site 0704)

    Houston, Texas · Recruiting

  • Futuro Clinical Trials ( Site 0703)

    McAllen, Texas · Recruiting

  • Endeavor Clinical Trials PA ( Site 0700)

    San Antonio, Texas · Recruiting

  • JBR Clinical Research ( Site 0702)

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.